Parsight Medical Unveils AI-Powered Multidisciplinary Oncology Solution at ASTRO 2024

From September 29 to October 2, 2024, the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO) was grandly held in Washington, D.C., the capital of the United States. This premier global event in the field of radiation oncology attracted more than 10,000 professionals and over 200 exhibitors from around the world. It featured 79 academic sessions and presented more than 1,700 scientific posters, bringing attendees together to discuss the latest advances in cancer treatment and expand the frontiers of innovation in radiation therapy.

The theme of this year's annual conference is "Targeting Provider Wellness for Exceptional Patient Care”, as stated by Conference Chair Professor Howard Sanler: “I hope this theme, which has run throughout the conference, will stimulate discussion on how to achieve a healthy balance between work, family, and personal life, thereby improving treatment outcomes for (oncology) patients.”As an innovative leader in the field of precision oncology treatment in China and globally, PVmed has officially launched the “Intelligent Multidisciplinary Team (AI-MDT) Treatment Solution for Cancer,” following nearly three years of dedicated research and continuous exploration.

PVmed’s AI-Enabled Multidisciplinary Team (AI-MDT) Solution for Oncology leverages cutting-edge artificial intelligence and image analysis technologies to enhance two major oncological interventions: radiation therapy and surgical treatment. Covering the entire workflow—from tumor screening, automatic delineation of radiation targets, and multimodal image fusion, to preoperative surgical planning, intraoperative navigation, and postoperative follow-up—the solution provides intelligent support and closed-loop services for the integrated multidisciplinary management of radiation and surgical oncology.During the four-day exhibition, this solution garnered widespread attention, attracting numerous domestic and international experts to observe demonstrations and personally experience the product, ultimately earning high acclaim.

This suite not only includes the four flagship products of AI-MDT, which boast exceptional performance:

PV-iCurve Pro: Automatic Delineation System for Radiotherapy Target Volumes

PV-iDose: Intelligent Analysis System for Radiotherapy Dose

PV-iCAD: Intelligent Auxiliary Diagnostic System

PV-iVision: Intelligent Surgical Assistance Planning System

It also features four brand-new products making their debut at ASTRO 2024:

PV-iFusion: A multimodal image fusion product whose fusion speed and quality both reach the world’s leading level

PV-iLearning: A Zero-Code Model Training Tool Customized to Match Physicians’ Image Annotation Styles

PV-iSpectra: Radiotherapy Multi-Sequence Spectral Image Delineation and Fusion System Developed for Philips Spectral CT

PV-iTherapy: Cervical Cancer Online Adaptive Radiotherapy Delineation Software Custom-Developed for Elekta Linear Accelerators

PV-iFusion: Developed specifically to meet the needs of multimodal image registration and fusion, PV-iFusion holds significant importance in clinical applications for radiotherapy target delineation and treatment. It enables users to precisely define organ and target contours by integrating multimodal imaging data. PV-iFusion provides intelligent image registration tools that perform one-click rigid and deformable registration across CT-CT, CT-CBCT, CT-Spectral CT, CT-MRI, and MRI-MRI modalities, while also supporting manual fine-tuning by users. Additionally, users can adjust various algorithm parameters to optimize fusion performance. Beyond utilizing image grayscale information, the fusion algorithm incorporates reliable biological model data, thereby enhancing the reliability of registration results. The speed and quality of its registration capabilities have reached an internationally advanced level.

PV-iLearning: can quickly help doctors train and generate contouring models that align with their personal style, “PVmed currently serves over 500 hospitals in China, with more than 500,000 patient cases managed.Therefore, to accommodate the contouring styles and preferences of physicians across different regions, we have specially developed PV-iLearning, which enables doctors to easily train their own contouring models with a single click and zero coding.Professor Lu Yao, Founder and CTO of PVmed, introduced, “PV-iLearning employs a few-shot AI deep learning engine that requires as few as three cases to initiate training,”“This is also PVmed’s most distinguishing feature. We are constantly exploring every possibility, with the goal of enabling everyone to become a model architect—a goal we have indeed achieved. With the assistance of PV-iLearning, users can train high-quality models without any programming knowledge. Furthermore, all training data remains strictly within the hospital premises, ensuring maximum data privacy and security.”

In addition to the two new products mentioned above,In response to the clinical needs of customers in China and around the world, PVmed also showcased PV-iSpectra, co-developed with Philips, a globally renowned medical imaging equipment manufacturer, and PV-iTherapy, jointly developed with Elekta, a top-tier international radiation oncology provider.These two innovative radiotherapy products have been deployed for clinical use in China and will be expanded to other global markets. This not only demonstrates that PVmed’s professional expertise, core team, and innovation capabilities are recognized by global strategic partners and hospital clients, but also marks a significant step in the accelerated international expansion of Chinese enterprises.

PV-iSpectra: An all-in-one solution for intelligent spectral CT contouring and fusion, based on a web platform to adapt multi-sequence spectral CT images, enabling browsing and automatic contouring of spectral multimodal images, with reference to functional image linkage for modifications, empowering the target volume contouring process. It achieves automatic registration and contouring of multi-parametric functional CT images, addressing the challenge physicians face in making decisions amid multi-sequence, multi-parametric information. By integrating spectral CT images from different modalities, it delivers optimized contouring results, thereby facilitating the successful implementation of radiotherapy on spectral CT and ushering in a new era of smart spectral imaging-driven radiotherapy workflows.

PV-iTherapy: An online adaptive radiotherapy (ART) solution for cervical cancer, based on the Elekta medical linear accelerator, utilizes low-dose cone-beam CT (CBCT) images converted into high-quality synthetic CT (sCT) images via AI to help clinicians track disease progression during radiotherapy. Meanwhile, it can generate high-precision contours of targets and organs at risk for each single fraction based on sCT in real time, with support for rapid modification. This assists physicians in quickly evaluating cumulative dose errors to organs at risk during treatment, providing dosimetric clinical decision support for adjusting radiotherapy plans and customizing ART strategies, ultimately achieving efficient online ART for cervical cancer and enabling the completion of the first single-fraction treatment within 20 minutes.

The new AI-MDT product showcased by PVmed not only represents the forefront of current intelligent precision oncology treatment technologies, but also demonstrates PVmed’s firm commitment and robust capability in advancing global cancer care.

During the exhibition, the PVmed team not only hosted domestic experts who traveled from Beijing, Tianjin, Jinan, Shanghai, Chengdu, Guangzhou, Hong Kong, and other regions for visits and exchanges, but also specially invitedMD Anderson Cancer Center, Johns Hopkins Hospital, Stanford Medicine, UC San Diego Health, etc.Distinguished scholars from overseas medical institutions made a special visit to the PVmed booth to experience new product demos and engage in in-depth discussions. The topics covered not only the latest advancements in academic research but also innovative applications in clinical practice and the future direction of the industry. Through collaborative discussions with top-tier industry experts and global partners, we have gained a clearer understanding of the market potential and application prospects of our AI-MDT solution. We are confident that, with continuous technological advancements and gradual market maturation, the AI-MDT solution will bring revolutionary benefits to related fields.

Dr. Dhruv Kacker, Senior Business Manager, PVmed Internationalstated: “Our intelligent multidisciplinary oncology treatment solution provides comprehensive coverage and management of the entire radiotherapy and surgical care continuum for cancer patients, facilitating collaborative care by multidisciplinary teams. All functional modules can be rapidly integrated, significantly enhancing treatment efficiency.”

As is well known, cancer has become one of the major diseases threatening human health. PVmed has chosen to focus on intelligent, precision-based, multidisciplinary collaborative cancer treatment, driven by its profound insight into the needs of clinical practice, physicians, and patients, as well as its unwavering commitment to technological innovation. With leading technological advantages and extensive experience in mature application scenarios within the field of AI-driven oncology, PVmed’s core team combines deep clinical expertise with rich innovation experience, laying a solid foundation for the company’s in-depth development in this sector.

In terms of business progress, PVmed has established collaborative partnerships with numerous medical institutions both domestically and internationally, jointly promoting the application and dissemination of AI-driven cancer treatment technologies. As its business continues to expand and deepen, PVmed has not only achieved remarkable success in the Chinese market but also joined hands with international partners to further explore additional application scenarios and possibilities for AI-MDT cancer treatment technology.

The commercial implementation of artificial intelligence in oncology treatment is the product of a close integration between clinical needs and industry trends.As One of the Few Global AI-MDT Oncology Treatment Service Providers, PVmed has developed a series of smart precision oncology treatment products by leveraging its independently developed artificial intelligence technology and combining it with a deep understanding of clinical needs. Centered on patients, the company formulates scientific and comprehensive individualized treatment plans to meet patients’ expectations for personalized and precise therapeutic strategies, while further responding to market demand for smart precision oncology treatment solutions.

In the global market, numerous startups are leveraging artificial intelligence to drive innovation and foster a vibrant landscape across various clinical applications. With its robust technological capabilities and mature commercial strategies, PVmed attracted significant attention from international medical institutions, manufacturers, and partners during ASTRO 2024, resulting in multiple letters of intent for collaboration. This has laid a solid foundation for the commercial expansion of AI-driven Multidisciplinary Team (AI-MDT) oncology treatments in North America and other international markets.

Dr. Xu Chenyang, President and Co-Chairman of PVmed, IEEE Fellow“The four new products we launched at ASTRO 2024 are revolutionizing cancer treatment technology. By integrating next-generation, AI-driven radiation therapy and surgical oncology, our innovative AI-MDT series solutions have established a new paradigm, empowering clinicians worldwide to deliver faster, more personalized treatments and accelerating industry advancement.” With the successful conclusion of this year’s ASTRO Annual Meeting, PVmed has not only showcased its innovative capabilities in intelligent, precision-based multidisciplinary oncology care and comprehensive AI-MDT solutions to the world, but also further solidified its position as an industry pioneer.

PVmed will continue to collaborate with global partners, leveraging technological innovation as a driving force to advance the application of AI technologies in oncology treatment, thereby making greater contributions worldwide to enhancing the well-being of healthcare professionals and strengthening patient care.